Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Obeid

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|September 17, 2009
Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptidesMichel Obeid
Revue Medicale Suisse|January 11, 2019
[Side effects of cancer immunotherapies : important role for the clinical immunologist]Michel Obeid
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulinMichel Obeid
Nature Reviews. Clinical Oncology|June 18, 2020
Personalized treatment of immune-related adverse events - balance is requiredFilipe Martins, Michel Obeid
The Lancet. Rheumatology|July 12, 2021
Reactivation of IgA vasculitis after COVID-19 vaccinationMichel Obeid, Craig Fenwick, Giuseppe Pantaleo
Cancer Immunology, Immunotherapy : CII|April 15, 2017
Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"?Gaël Deplanque, Keyvan Shabafrouz, Michel Obeid
Neoplasia (New York, N.Y.)|December 30, 2017
Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based ImmunotherapyFilipe Martins, Grégoire Stalder, Michel Obeid
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactionsAlfredo Addeo, Michel Obeid, Alex Friedlaender
JAMA Oncology|January 17, 2020
A Diffuse Medullary Hypercaptation With No Bone LesionAlexia Christin, Laurence de Leval, Michel Obeid
Revue Medicale Suisse|November 25, 2020
[Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view]Christophe Cisarovsky, Vanessa Kraege, Michel Obeid, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|September 17, 2009
Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptidesMichel Obeid
Revue Medicale Suisse|January 11, 2019
[Side effects of cancer immunotherapies : important role for the clinical immunologist]Michel Obeid
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulinMichel Obeid
Nature Reviews. Clinical Oncology|June 18, 2020
Personalized treatment of immune-related adverse events - balance is requiredFilipe Martins, Michel Obeid
The Lancet. Rheumatology|July 12, 2021
Reactivation of IgA vasculitis after COVID-19 vaccinationMichel Obeid, Craig Fenwick, Giuseppe Pantaleo
Cancer Immunology, Immunotherapy : CII|April 15, 2017
Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"?Gaël Deplanque, Keyvan Shabafrouz, Michel Obeid
Neoplasia (New York, N.Y.)|December 30, 2017
Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based ImmunotherapyFilipe Martins, Grégoire Stalder, Michel Obeid
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactionsAlfredo Addeo, Michel Obeid, Alex Friedlaender
JAMA Oncology|January 17, 2020
A Diffuse Medullary Hypercaptation With No Bone LesionAlexia Christin, Laurence de Leval, Michel Obeid
Revue Medicale Suisse|November 25, 2020
[Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view]Christophe Cisarovsky, Vanessa Kraege, Michel Obeid, et al.
Pageof 5